Jayson Bedford
Stock Analyst at Raymond James
(4.02)
# 409
Out of 4,814 analysts
306
Total ratings
55.02%
Success rate
7.39%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Outperform | $132 → $142 | $129.70 | +9.48% | 28 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $162 → $164 | $157.44 | +4.17% | 23 | Apr 16, 2025 | |
| PODD Insulet | Reiterates: Outperform | $294 → $328 | $246.95 | +32.82% | 26 | Feb 21, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $126 → $119 | $97.88 | +21.58% | 7 | Feb 7, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $119 → $122 | $95.25 | +28.08% | 24 | Feb 6, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $482.40 | +42.62% | 8 | Jan 24, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $105 → $110 | $90.82 | +21.13% | 26 | Dec 31, 2024 | |
| MASI Masimo | Maintains: Outperform | $170 → $194 | $152.40 | +27.30% | 6 | Dec 27, 2024 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $68.61 | +44.29% | 30 | Oct 25, 2024 | |
| ICUI ICU Medical | Maintains: Outperform | $158 → $190 | $138.67 | +37.02% | 19 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $200.40 | +34.73% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $15.56 | -16.45% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $9.53 | +4.93% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $129.55 | +109.19% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.32 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $16.86 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $71.56 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $28.89 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $82.70 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.61 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $57.55 | +49.44% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.63 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.80 | - | 3 | Jan 2, 2018 |
Abbott Laboratories
Apr 17, 2025
Maintains: Outperform
Price Target: $132 → $142
Current: $129.70
Upside: +9.48%
Johnson & Johnson
Apr 16, 2025
Maintains: Outperform
Price Target: $162 → $164
Current: $157.44
Upside: +4.17%
Insulet
Feb 21, 2025
Reiterates: Outperform
Price Target: $294 → $328
Current: $246.95
Upside: +32.82%
Zimmer Biomet Holdings
Feb 7, 2025
Maintains: Outperform
Price Target: $126 → $119
Current: $97.88
Upside: +21.58%
Boston Scientific
Feb 6, 2025
Maintains: Strong Buy
Price Target: $119 → $122
Current: $95.25
Upside: +28.08%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $482.40
Upside: +42.62%
Merit Medical Systems
Dec 31, 2024
Maintains: Outperform
Price Target: $105 → $110
Current: $90.82
Upside: +21.13%
Masimo
Dec 27, 2024
Maintains: Outperform
Price Target: $170 → $194
Current: $152.40
Upside: +27.30%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $68.61
Upside: +44.29%
ICU Medical
Sep 12, 2024
Maintains: Outperform
Price Target: $158 → $190
Current: $138.67
Upside: +37.02%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $200.40
Upside: +34.73%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $15.56
Upside: -16.45%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $9.53
Upside: +4.93%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $129.55
Upside: +109.19%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.32
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $16.86
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $71.56
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $28.89
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $82.70
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.61
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $57.55
Upside: +49.44%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.63
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $15.80
Upside: -